|Videos|December 5, 2022

Latest research supporting stereotactic radiotherapy for oligometastatic renal cell carcinoma

“Stereotactic radiation can delay the initiation of systemic therapy; it can locally control oligometastatic RCC patients for as much as 2 years,” says Raquibul Hannan, MD, PhD.

At the SUO 23rd Annual Meeting, Raquibul Hannan, MD, PhD, the latest research findings showing positive results with stereotactic radiotherapy in patients with oligometastatic renal cell carcinoma. Hannan is a professor in the Department of Radiation Oncology, Urology and Immunology at the University of Texas Southwestern Medical Center in Dallas.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.


Latest CME